Systimmune
Updates & Highlights
Clinical Trials Arena · about 1 month ago
SystImmune doses first patient in Phase III trial for ES-SCLC
PR Newswire · about 1 month ago
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
AllSci · about 2 months ago
SystImmune's iza-bren wins China approval for esophageal...
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Systimmune?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentSystImmune doses first patient in Phase III trial for ES-SCLC
SystImmune doses first patient in Phase III trial for ES-SCLC
Clinical Trials Arena · about 1 month ago
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
PR Newswire · about 1 month ago
SystImmune's iza-bren wins China approval for esophageal...
SystImmune's iza-bren wins China approval for esophageal...
AllSci · about 2 months ago
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
goSkagit · about 2 months ago
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
PR Newswire · about 2 months ago
SystImmune, Biokin secure first China approval for bispecific ADC iza-bren
SystImmune, Biokin secure first China approval for bispecific ADC iza-bren
BioSpectrum Asia · 3 months ago
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies
Yahoo Finance · 3 months ago
SystImmune, Biokin secure first China approval for bispecific ADC iza-bren
SystImmune, Biokin secure first China approval for bispecific ADC iza-bren
BioSpectrum Asia · 3 months ago
SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
PR Newswire · 3 months ago
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
PMLiVE · 3 months ago
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
PR Newswire · 3 months ago
SystImmune's ADC Pipeline Shines Ahead of ASCO with Major Cancer Data
SystImmune's ADC Pipeline Shines Ahead of ASCO with Major Cancer Data
BriefGlance · 4 months ago
SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis
SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis
Oncology Pipeline · 4 months ago
SystImmune starts another first-line phase 3 | ApexOnco - Clinical Trials news and analysis
SystImmune starts another first-line phase 3 | ApexOnco - Clinical Trials news and analysis
Oncology Pipeline · 5 months ago
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
PR Newswire · 6 months ago
Systimmune’s iza-bren hits phase III breast cancer goals in China
Systimmune’s iza-bren hits phase III breast cancer goals in China
BioWorld News · 6 months ago
SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial
SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial
BioPharma APAC · 6 months ago
SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial
SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial
BioPharma APAC · 6 months ago
Systimmune’s iza-bren hits phase III breast cancer goals in China
Systimmune’s iza-bren hits phase III breast cancer goals in China
bioworld.com · 6 months ago
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Seeking Alpha · 7 months ago